Rafael Holdings, Inc. (NYSE:RFL) Short Interest Update

Rafael Holdings, Inc. (NYSE:RFL) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 189,800 shares, an increase of 55.7% from the March 15th total of 121,900 shares. Based on an average daily volume of 34,600 shares, the days-to-cover ratio is presently 5.5 days. Currently, 0.9% of the shares of the company are sold short.

Rafael Trading Up 2.2 %

NYSE:RFL traded up $0.04 during mid-day trading on Thursday, hitting $1.64. The company’s stock had a trading volume of 8,296 shares, compared to its average volume of 34,308. Rafael has a fifty-two week low of $1.29 and a fifty-two week high of $2.50. The company has a market capitalization of $40.73 million, a price-to-earnings ratio of -0.98 and a beta of 0.99. The stock has a fifty day moving average of $1.89 and a 200-day moving average of $1.91.

Rafael (NYSE:RFL) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.06) earnings per share for the quarter. Rafael had a negative return on equity of 53.71% and a negative net margin of 5,707.03%. The firm had revenue of $0.08 million for the quarter.

Hedge Funds Weigh In On Rafael

Several large investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Rafael in the 1st quarter valued at about $26,000. Geode Capital Management LLC raised its position in Rafael by 17.9% in the 4th quarter. Geode Capital Management LLC now owns 174,561 shares of the company’s stock valued at $288,000 after buying an additional 26,493 shares during the last quarter. Finally, Peapod Lane Capital LLC bought a new stake in Rafael in the 4th quarter valued at approximately $553,000. 11.30% of the stock is currently owned by institutional investors and hedge funds.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.